Product Description
Propylene glycol 0.3%, Polyethylene glycol 400 0.5%, and Glycerin 0.2%. Ophthalmic solution. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT06375343?term=pro240&draw=2&rank=1)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Ophthalmic
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Laboratorios Sophia S.A de C.V.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Dry Eye Disease|Dry Eye Syndromes|Keratoconjunctivitis Sicca
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
SOPH240-0923/I | P1 |
Not yet recruiting |
Dry Eye Disease|Dry Eye Syndromes|Keratoconjunctivitis Sicca |
2024-10-30 |
21% |